EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom

Kola Adegoke iD, Olajide Alfred Durojaye, Abimbola Adegoke iD, Adeyinka Adegoke iD

Health Services Insights · 2026-05 · 19

DOI: 10.1177/11786329261448992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Services Insights, online erschienen am 19.05.2026. Verfasst von Kola Adegoke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health and Biomedical Sciences, College of Health Professions, University of Texas Rio Grande Valley, Edinburg, TX, USA. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Soaring drug prices pose a significant obstacle to affordable and equitable access to medicines in high-income healthcare systems. This study compares two leading reform tool families, Most Favored Nation (MFN)/international reference pricing (IRP) and value-based contracting (VBC), across the United States, Canada, and the United Kingdom, with attention to cost containment, value-linked incentive design, equity of access, and implementation feasibility. U.S. policy developments (CMS Innovation Center’s GENEROUS, GLOBE, and GUARD models) extend international benchmark-based design options beyond the 2020 MFN rule.

Methods

Guided by institutional and governance theories, we conducted a structured comparative policy analysis using a four-dimensional trade-off matrix. Cases from the United States, Canada, and the United Kingdom were selected using a most-different-systems design. Documents from 2007 to 2025 were coded for cost containment, value-linked incentive design, equity, and implementation feasibility. To reduce subjectivity, scores were assigned using prespecified rubric anchors, conservative scoring rules for borderline cases, and a sensitivity check of adjacent-score judgments. Design-stage U.S. benchmark-based model materials assessed on March 5, 2026, were incorporated descriptively and not considered as outcome evidence.

Results

The United Kingdom model, centered on the National Institute for Health and Care Excellence (UK NICE) and the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), was most consistently aligned across all four dimensions (design-feature alignment). Canada’s Patented Medicine Prices Review Board (PMPRB) supports affordability and baseline access, with implementation variation across provinces and more limited adoption of outcomes-based contracting. U.S. MFN/IRP initiatives and VBC pilots show lower alignment on equity and feasibility in a multi-payer environment characterized by contested authority and variable data/contracting capacity. Emerging CMS Innovation Center proposals (GENEROUS, GLOBE, GUARD) indicate continued federal interest in benchmark-based designs, but empirical impacts remain to be evaluated.

Conclusions

MFN/IRP anchoring and VBC are implementation-intensive tools whose performance depends on institutional fit. A hybrid approach, using international benchmarks as inputs for negotiations and expanding value-linked agreements where measurement and governance prerequisites are met, may offer a more feasible U.S. pathway. This study provides a repeatable framework for assessing drug pricing reforms and illustrates how institutional alignment conditions the implementability of tools. Design-feature scores reflect policy design and governance capacity, not realized outcomes.

Schlagwörter

Stichwörter der Autor:innen

Centers for Medicare and Medicaid ServicesU.S.comparative policy analysis (United States, Canada, United Kingdom)governance and policy capacityimplementation feasibilityinternational reference pricing (IRP)/most-favored-nation (MFN)pharmaceutical pricing policyvalue-based contracting (VBC)/outcomes-based agreements

Autor:innen und Institutionen

  • Department of Health and Biomedical Sciences, College of Health Professions, University of Texas Rio Grande Valley, Edinburg, TX, USA.
  • School of Health Sciences and Practice, New York Medical College, Valhalla, NY, USA.
  • Carleton Medical Clinic, Albert, AB, Canada.
  • McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston (UTHealth), TX, USA.
  • Department of Business Administration, Northern Alberta Institute of Technology, Edmonton, AB, Canada.

ORCID-Profile: Kola Adegoke, Abimbola Adegoke, Adeyinka Adegoke

Zitieren

APA

Adegoke, K., Durojaye, O. A., Adegoke, A., & Adegoke, A. (2026). Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom. Health Services Insights, 19. https://doi.org/10.1177/11786329261448992

Vancouver

Adegoke K, Durojaye OA, Adegoke A, Adegoke A. Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom. Health Services Insights. 2026;19. doi:10.1177/11786329261448992

BibTeX
@article{Adegoke2026,
  author = {Adegoke, Kola and Durojaye, Olajide Alfred and Adegoke, Abimbola and Adegoke, Adeyinka},
  title = {Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom},
  journal = {Health Services Insights},
  year = {2026},
  volume = {19},
  doi = {10.1177/11786329261448992}
}
Kostenlos starten →